How a better image can save a life
The Globe and Mail: How a better image can save a life Sharon Needham, with oncologist Dr. Daniel Rayson, and radiologist Dr. Steven Burrell, at [...]
The Globe and Mail: How a better image can save a life Sharon Needham, with oncologist Dr. Daniel Rayson, and radiologist Dr. Steven Burrell, at [...]
Disclaimer: CNETS is a patient organization, and we are unable to provide medical advice. Any information or guidance contained herein should not replace personalized medical advice. Our objective is [...]
CNETS is happy to announce that BC Cancer will now reimburse LUTATHERA for the approved indication. The BC Cancer Benefit Drug List, Published March 2021, Tumour Site: Gastrointestinal Peptide [...]
INSPIRATIONAL NEUROENDOCRINE CANCER PATIENT STORY Long-time CNETS fundraisers Bryde Fresque and Natalie Mezey, share a message of hope! As outlined in this Ottawa Hospital Foundation report, Bryde Fresque [...]
Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Published January 19, 2021 Highlights This updated ESMO Clinical Practice Guideline [...]
Article: Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era February 2021 - European Journal of Cancer, Review [...]
INCA GLOBAL NET PATIENT INFO PACK NEW FOR 2020! - NETInfo INCA launches a range of factsheets on NETs that are free to download. These factsheets provide [...]
Radiopharmaceutical cancer treatment Lutathera® now available to Ontario patients with midgut neuroendocrine tumours (NETs). The Ontario funding criteria covers the treatment of adult patients with somatostatin receptor-positive (SSR+) midgut NETs [...]
As of September 30, 2020, the Québec Ministry of Health and Social Services has listed Lutathera on the Liste de Médicaments – Établissements. Lutathera will be reimbursed for GEP-NETs patients [...]
As of August 1, 2020, patients with midgut, GEP-NETs will now be eligible for treatment with LUTATHERA® [lutetium (177Lu) oxodotreotide]. This listing covers adult patients with somatostatin receptor-positive (SSR+) midgut [...]